synagis
synagis Uses, Dosage, Side Effects, Food Interaction and all others data.
Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor (1) and Cess (2). The human lightchain sequence was derived from the constant domain of Ck and the variable framework regions of the VL gene K104 withJk-4. synagis is expressed from a stable murine (mouse) myeloma cell line (NS0). synagis is composed of to heavy chains (50.6 kDa each) and two light chains (27.6 kDa each), contains 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF)
Synagis exhibits neutralizing and fusion-inhibitory activity against Respiratory syncytial virus (RSV). These activities inhibit RSV replication or spread. Synagis is given to prevent the development of lower respiratory tract disease in pediatric patients.
Trade Name | synagis |
Availability | Prescription only |
Generic | Palivizumab |
Palivizumab Other Names | Palivizumab |
Related Drugs | ribavirin, Synagis, respiratory syncytial virus immune globulin, RespiGam |
Weight | 100mg/ml, |
Type | Solution, Injection*, Injection, Intramuscular Solution |
Groups | Approved, Investigational |
Therapeutic Class | |
Manufacturer | Abbvie Limited, Abbvie Ltd |
Available Country | Saudi Arabia, Australia, Canada, United Kingdom, United States, France, Italy, Netherlands, Portugal, Spain, |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
synagis is a monoclonal anti respiratory syncytial virus F protein antibody used to prevent serious sequelae caused by respiratory syncytial virus infection in pediatric patients.
For prophylaxis of respiratory diseases casued by respiratory syncytial virus.
synagis is also used to associated treatment for these conditions: Infections, Respiratory Syncytial Virus
How synagis works
synagis binds to the fusion glycoprotein of RSV. This prevents its binding and uptake by host cellular receptors.
Food Interaction
No interactions found.synagis Disease Interaction
Half Life
18-20 days (in adults)
Innovators Monograph
You find simplified version here synagis